The ADDF provides funding to academic centers and biotechs from around the world that are advancing therapeutic and biomarker development for Alzheimer's and related dementias. The funding is focused on IND-enabling studies and early-stage clinical trials, development and validation of biomarkers, and clinical trials testing drug use. Applications are reviewed throughout the year with specific deadlines for different stages of the application process.